XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · Real-Time Price · USD
0.8502
+0.0001 (0.02%)
Jan 28, 2026, 12:12 PM EST - Market open
XTL Biopharmaceuticals Revenue
XTL Biopharmaceuticals had revenue of $258.50K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $968.00K. In the year 2024, XTL Biopharmaceuticals had annual revenue of $451.00K.
Revenue (ttm)
$968.00K
Revenue Growth
n/a
P/S Ratio
8.81
Revenue / Employee
$96,800
Employees
10
Market Cap
8.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 451.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 8.02M |
| Immuron | 4.78M |
| SeaStar Medical Holding | 881.00K |
| BioRestorative Therapies | 383.40K |
| Pulmatrix | 3.00K |
| Ernexa Therapeutics | 1,000.00 |
XTLB News
- 4 days ago - XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - GlobeNewsWire
- 15 days ago - XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership - GlobeNewsWire
- 4 weeks ago - XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency - GlobeNewsWire
- 10 months ago - XTL Names Mr. Noam Band as its New Chief Executive Officer - GlobeNewsWire
- 1 year ago - XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million - GlobeNewsWire
- 1 year ago - XTL Entered Definitive Agreement to Acquire The Social Proxy - GlobeNewsWire
- 2 years ago - XTL To Aquire The Social Proxy - GlobeNewsWire
- 2 years ago - XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel - GlobeNewsWire